ライフサイエンスコーパス: subcutaneously

1 or azacitidine (75 mg/m(2), days 1-7, IV or subcutaneously).

2 nfected with ZIKV (French Polynesian strain) subcutaneously.

3 e redundancy of the extension wire is placed subcutaneously.

4 protective when administered intranasally or subcutaneously.

5 imilar to those observed in animals infected subcutaneously.

6 onnected to a dual-channel stimulator placed subcutaneously.

7 with microinjection ports and then implanted subcutaneously.

8 le to that of full dose zoster vaccine given subcutaneously.

9 s was used to vaccinate mice intranasally or subcutaneously.

10 , allowing the entire device to be implanted subcutaneously.

11 otocol was repeated with anakinra (100 mg/d) subcutaneously.

12 e highly protective, as is H84T administered subcutaneously.

13 ent at a once-daily dose of 3.0 mg, injected subcutaneously.

14 sts or vehicle (5 ml/kg saline) was injected subcutaneously.

15 Control mice were vaccinated subcutaneously.

16 administered to BALB/c mice either orally or subcutaneously.

17 nce the first attempts, AIT was administered subcutaneously.

18 eliable volumetric data for tumors grown non-subcutaneously.

19 tivated bacterial-based stimuli administered subcutaneously.

20 ptor excitation via injection of acetic acid subcutaneously.

21 peptides on food intake, mice were injected subcutaneously (1000 nmol/kg) and food intake was assess

22 placebo or methotrexate (intramuscularly or subcutaneously, 25 mg weekly) for 24 weeks.

23 injected in double-blind, randomized fashion subcutaneously 30 min before an oral glucose tolerance t

24 tabilized with morphine, 30 mg, administered subcutaneously 4 times daily.

25 and expansion cohorts were given emicizumab subcutaneously 6 mg/kg every 4 weeks for 24 weeks or mor

26 followed by maintenance doses of 6 mg/kg) or subcutaneously (600 mg), given in combination with chemo

27 ry other week) or etanercept (50 mg per week subcutaneously) according to the patient's and rheumatol

28 olyinosinic:polycytidylic acid or were given subcutaneously, activatory FcgammaR could also provide c

29 asfotase alfa (1 mg/kg three times per week subcutaneously, adjusted to 3 mg/kg three times per week

30 There was less accumulation of subcutaneously administered (54)Mn in the liver, gallbla

31 Adult female CD1 mice were subcutaneously administered a combination of cadmium chl

32 Our data show that intranasally but not subcutaneously administered BCG confers robust protectio

33 The phase 1b PAVO (MMY1004) study evaluated subcutaneously administered daratumumab in combination w

34 Compared with subcutaneously administered drugs, oral formulations cre

35 rted, showing efficacy and safety similar to subcutaneously administered insulin glargine.

36 To understand the mechanisms, we subcutaneously administered KGF to mice 24 hours before

37 Treatment with subcutaneously administered pegbelfermin for 16 weeks wa

38 gue, PYY-AP3H, has potential as a once-a-day subcutaneously administered preparation for the treatmen

39 lectronic interactive response technology to subcutaneously administered quarterly fremanezumab (mont

40 was further improved if recipient mice were subcutaneously administered treprostinil (0.15 mg kg(-1)

41 Emicizumab, a subcutaneously administered, humanised, bispecific, mono

42 treatment phase, with loading doses (120 mg subcutaneously) administered on study days 8 and 15 to p

43 out IFN-alpha-2b (0.5 to 1.0 mug/kg per week subcutaneously, after chemotherapy until 2 years postreg

44 When administered subcutaneously, ALN-AT3 showed potent, dose-dependent, a

45 In contrast, islets transplanted subcutaneously alone failed to engraft.

46 activated BVDV vaccine (IAV), all inoculated subcutaneously and boosted prior to BVDV-1 challenge.

47 o drisapersen 6 mg/kg or placebo, each given subcutaneously and either continuously (once weekly) or

48 nd inhibit miR-21 function when administered subcutaneously and evaluated the therapeutic potential o

49 ed with approximately 10(6) MDA-MB-231 cells subcutaneously and imaged with (18)F-NaF PET/CT in a 120

50 with both Freund's and alum adjuvants, given subcutaneously and intramuscularly, respectively, with a

51 ration significantly delayed tumor growth of subcutaneously and orthotopically implanted tumors in nu

52 ived volume resuscitation (1 mL saline/mouse subcutaneously) and antibiotics (meropenem 10 mg/kg intr

53 ceived a range of nalbuphine doses or saline subcutaneously as: (1) monotherapy, (2) acute coadminist

54 MAD subjects received evinacumab subcutaneously at 150/300/450 mg once weekly, 300/450 mg

55 Guadecitabine given subcutaneously at 60 mg/m(2) daily x 5 is well tolerated

56 SAD subjects received evinacumab subcutaneously at 75/150/250 mg, or intravenously at 5/1

57 osis to compare daclizumab HYP, administered subcutaneously at a dose of 150 mg every 4 weeks, with i

58 Galcanezumab administered subcutaneously at a dose of 300 mg once monthly reduced

59 roup A (n = 24), bermekimab was administered subcutaneously at a dose of 400 mg weekly (13 doses) in

60 roup B (n = 18), bermekimab was administered subcutaneously at a dose of 400 mg weekly (13 doses) in

61 Erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg sign

62 t a dose of 300 mg) or placebo, administered subcutaneously at baseline and at 1 month.

63 mg per kilogram of body weight) administered subcutaneously at baseline, week 4, and week 8, as compa

64 300 mg secukinumab was administered subcutaneously at baseline, weeks 1, 2, 3, and 4, and th

65 AM0010 was self-administered subcutaneously at doses of 1 to 40 mug/kg once per day.

66 neously at weeks 0 and 4 or 80 mg adalimumab subcutaneously at randomisation, then 40 mg at weeks 1,

67 of killing Streptococcus pyogenes introduced subcutaneously at the bioadhesive's surface, with minima

68 to receive adalimumab 0.8 mg/kg or 0.4 mg/kg subcutaneously at week 0, then every other week starting

69 Tildrakizumab was administered subcutaneously at weeks 0 and 4 during part 1 and at wee

70 se technology to receive 150 mg risankizumab subcutaneously at weeks 0 and 4 or 80 mg adalimumab subc

71 ralizumab 120 mg or visually matched placebo subcutaneously at weeks 0, 2, 4, and every 4 weeks there

72 mL 0.9% saline or 1 mL (100 mug) octreotide subcutaneously before completing a progressive ratio tas

73 loads in the serum and brain when inoculated subcutaneously but remaining neurovirulent when inoculat

74 the brains of infected mice when inoculated subcutaneously but replicate well following intracranial

75 on techniques both place the pulse generator subcutaneously, but the 2-incision technique omits the s

76 itoring mineralization of scaffold implanted subcutaneously by demonstrating the ability to measure t

77 gle-use 3 mL vials and was self-administered subcutaneously by injection at home at 10 mug/kg or 20 m

78 tesamorelin, 2 mg (n=28), or placebo (n=22), subcutaneously daily for 6 months.

79 either azacitidine 75 mg/m(2) intravenously/subcutaneously daily or decitabine 20 mg/m(2) intravenou

80 d IV (days 2-5), and GM-CSF was administered subcutaneously (days 6-12).

81 azacitidine maintenance (N = 56; 50 mg/m(2), subcutaneously, days 1-5, every 4 weeks) until relapse,

82 treated by 2-CdA (0.14 mg/kg in infusion or subcutaneously, days 1-5; repeated at 4-12 weeks until 1

83 Transgenic Il31 overexpression and subcutaneously delivered IL-31 induced an increase in th

84 (250 mug/m2/d) or placebo were administered subcutaneously (double-blinded) 3 times/wk for the first

85 enralizumab (at a dose of 30 mg administered subcutaneously either every 4 weeks or every 8 weeks [wi

86 nction correlated to the improved control of subcutaneously established murine melanoma after adoptiv

87 to receive 150 mg of bococizumab or placebo subcutaneously every 2 weeks and who were followed for u

88 avenously) followed by pegylated G-CSF (6 mg subcutaneously every 2 weeks for 6 doses) and 8 subjects

89 to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo.

90 lind study of alirocumab 150 mg administered subcutaneously every 2 weeks to 13 patients representing

91 apy were randomized to alirocumab or placebo subcutaneously every 2 weeks.

92 ing to body weight) or placebo, administered subcutaneously every 2 weeks.

93 Alirocumab 75 mg or placebo was administered subcutaneously every 2 weeks.

94 ents received 0.2 to 1.25 mg/kg luspatercept subcutaneously every 21 days for >=5 cycles (dose-findin

95 anakinumab doses (50 mg, 150 mg, and 300 mg, subcutaneously every 3 months) or placebo.

96 ram of body weight) or placebo, administered subcutaneously every 3 weeks.

97 ither denosumab (120 mg) or matching placebo subcutaneously every 3-4 weeks, starting with neoadjuvan

98 tients received open-label MEDI2070 (210 mg) subcutaneously every 4 weeks from weeks 12 to 112.

99 Omalizumab 300 mg administered subcutaneously every 4 weeks reduced weekly ISS and othe

100 to a group that received lanreotide (120 mg subcutaneously every 4 weeks) and 82 to a group that rec

101 0 mg of mepolizumab or placebo, administered subcutaneously every 4 weeks, plus standard care, for 52

102 and immediately commenced mepolizumab 100 mg subcutaneously every 4 weeks.

103 ther denosumab 60 mg or placebo administered subcutaneously every 6 months in 58 trial centres in Aus

104 were obtained with inclisiran, administered subcutaneously every 6 months.

105 denosumab 60 mg (n=1711) or placebo (n=1709) subcutaneously every 6 months.

106 s who received benralizumab (30 mg or 100 mg subcutaneously every 8 weeks; first three doses every 4

107 were randomised to IFNB1b 250 mug or placebo subcutaneously every other day.

108 group) or a TNF inhibitor-adalimumab (40 mg subcutaneously every other week) or etanercept (50 mg pe

109 herapy targeted to PCSK9 may be administered subcutaneously every two or four weeks.

110 m, to receive placebo or 100 mg benralizumab subcutaneously, every 4 weeks (three doses), then every

111 Options include denosumab, 120 mg subcutaneously, every 4 weeks; pamidronate, 90 mg intrav

112 MAD, 21 (67.7%) versus 9 (75.0%) subjects on subcutaneously evinacumab versus placebo and 6 (85.7%) v

113 saline or 1 mL (100 mug) octreotide acetate subcutaneously followed by a standardized ad libitum mea

114 lated UCN2 peptide (compound A) at 0.3 mg/kg subcutaneously for 14 days.

115 Omalizumab or placebo was administered subcutaneously for 16 weeks, with oral immunotherapy sta

116 sputatrix venom sublethal dose was injected subcutaneously for 3 consecutive days prior to SBI.

117 eks; or 20 mg every week), or saline placebo subcutaneously for 6 to 12 months.

118 Similarly, when LLC cells were implanted subcutaneously for the study of spontaneous tumor cell m

119 o assess the safety and clinical activity of subcutaneously given guadecitabine in patients with acut

120 Rats subcutaneously grafted with these cells were randomly as

121 Intratumoral injection of Mobilan into subcutaneously growing syngeneic prostate tumors in immu

122 Here we developed a subcutaneously implantable nanofluidic device for the su

123 In the work presented here, a subcutaneously implantable silicon PV cell, operated in

124 Additionally, ECs migrated less into subcutaneously implanted B16F0 melanoma tumors as assess

125 We show that for subcutaneously implanted cells, NIR bioluminescence prov

126 tly, KDM3A depletion inhibited the growth of subcutaneously implanted cisplatin-resistant human ovari

127 Mice bearing subcutaneously implanted H460 lung cancer xenografts wer

128 onitoring the mineralization in 3D scaffolds subcutaneously implanted in small animals.

129 The growth of CCA tumors subcutaneously implanted into immunodeficient mice was i

130 The growth of CCA tumors subcutaneously implanted into immunodeficient mice was i

131 resulted in defective and reduced growth of subcutaneously implanted Lewis lung carcinoma (LLC) and

132 IGF1 was delivered for 5 days using subcutaneously implanted mini-pumps in uninjured mice or

133 phage (TAM) and CD8 T cell infiltration into subcutaneously implanted murine lung carcinoma tumors.

134 ate (CycT) strongly suppresses the growth of subcutaneously implanted non-small cell lung cancer (NSC

135 kg per day) was administered to the mice via subcutaneously implanted osmotic minipumps for 28 days.

136 Subcutaneously implanted osmotic minipumps were used to

137 6) were infused with angiotensin II by using subcutaneously implanted osmotic pumps, with an addition

138 Subcutaneously implanted ossicles formed heterotopic bon

139 of miR-145 in ASCs enhanced angiogenesis in subcutaneously implanted plugs in mice.

140 d the role of PDGFRalpha was examined in the subcutaneously implanted sponge matrices.

141 d Prevotella intermedia, was inoculated into subcutaneously implanted titanium chambers.

142 oups of 6 adult female BALB/c nude mice with subcutaneously implanted tumors underwent microPET imagi

143 oups of 6 adult female BALB/c nude mice with subcutaneously implanted tumors underwent microPET imagi

144 e severe combined immunodeficiency mice were subcutaneously implanted with human prostate cancer LAPC

145 ign and efficacy of a novel prevascularized, subcutaneously implanted, retrievable poly (D,L-lactide-

146 e a single dose of 10-120 mg IONIS-APO(a)LRx subcutaneously in an ascending-dose design or placebo (i

147 es of 10 mg, 20 mg, or 40 mg IONIS-APO(a)LRx subcutaneously in an ascending-dose design or placebo (i

148 ulin-producing beta-cell line were implanted subcutaneously in autoimmune diabetes-prone NOD mice, be

149 When they were administered intranasally or subcutaneously in cotton rats, the candidates were highl

150 The dual capsules were implanted subcutaneously in immune competent ovariectomized C57BL/

151 etastatic to lung and liver when xenografted subcutaneously in immune-deficient NSG mice.

152 s of these scaffolds, or scaffolds implanted subcutaneously in live animals, are typically difficult

153 In vivo, R-VECs implanted subcutaneously in mice self-organize into durable pericy

154 After injecting this material subcutaneously in mice, optical imaging was used to quan

155 s liver metastasis was initially established subcutaneously in nude mice and the subcutaneous tumor t

156 les in TMJ-OA cartilage plugs were implanted subcutaneously in nude mice.

157 genic media (OM) for 13 d and then implanted subcutaneously in nude rats for 4 and 8 wk.

158 o-controlled trial with Alt a 1 administered subcutaneously in patients with allergic rhinoconjunctiv

159 riamcinolone acetonide (Tr-A) were implanted subcutaneously in rats by using a validated cage model,

160 ficiently biodegraded in vivo when implanted subcutaneously in rats.

161 nd possess low immunogenicity when implanted subcutaneously in rats.

162 ient-derived xenograft tumors were implanted subcutaneously in SCID mice.

163 and epidermoid (A431) tumors were implanted subcutaneously in six athymic mice.

164 collagen scaffolds (ossicles), and implanted subcutaneously in the flank region of 8 adult mice.

165 er the motor cortex and a transmitter placed subcutaneously in the left side of the thorax.

166 Mice were subcutaneously infected with a fully virulent Y. pestis

167 .5 mg thrice daily, together with octreotide subcutaneously: initial dose 100 mug thrice daily and up

168 hage colony-stimulating factor (125 mug/m(2) subcutaneously injected daily for 2 weeks, starting duri

169 BMCs subcutaneously injected in mice at the time of HSCT enha

170 n purposely contaminated with bacteria, were subcutaneously injected in mice.

171 es-loaded MNPs was 17.98+/-5.61% relative to subcutaneously injected insulin solution, with a 2-fold

172 a few hours longer than a 1 U kg(-1) dose of subcutaneously injected insulin.

173 ) derived from rectus abdominis muscles were subcutaneously injected into CD-1 nude mice (CD-1 nude m

174 er cells (mT3) from KPC mice (C57BL/6), were subcutaneously injected into Cdh11(+/+) (C57BL/6J) mice

175 Pancreatic cancer cells from KPC mice were subcutaneously injected into Cdh11(+/+) and Cdh11(-/-) m

176 Cells were subcutaneously injected into flanks of syngeneic mice an

177 ducible tagged SPDEF or vector (control) and subcutaneously injected into immunodeficient NSG mice.

178 capable of maintaining in vivo potency when subcutaneously injected into mice.

179 l of advanced biliary liver fibrosis how the subcutaneously injected microspheres released pPB-HSA in

180 participants (2:2:1:1) to either once-weekly subcutaneously injected semaglutide (0.5 mg or 1.0 mg),

181 nflammation, we found that OVA released from subcutaneously injected SHAS-OVA led to a sustained stim

182 Mice were subcutaneously injected with OVA or OVA with PAFR-antago

183 UP-XR (extended-release buprenorphine), is a subcutaneously injected, monthly buprenorphine treatment

184 was induced in male rats by SU5416 (25 mg/kg subcutaneously) injection followed by 4 weeks of hypoxia

185 perimental group and only detected in 20% of subcutaneously inoculated animals (derived from 1 experi

186 ncy of replication in major target organs in subcutaneously inoculated ducks.

187 Male nude rats were subcutaneously inoculated in the shoulder with ERalpha/E

188 DX-2930 injected subcutaneously into cynomolgus monkeys exhibited a long

189 or a further study, A/H-F/V was transplanted subcutaneously into ICR mice for up to 4 weeks to assess

190 These cryogels are injected subcutaneously into mice to localize transplanted tumour

191 human light chain amyloid extract, injected subcutaneously into mice, is rapidly cleared in a proces

192 cancer xenografts (LNCaP) were transplanted subcutaneously into mice.

193 atic adenocarcinoma specimens were implanted subcutaneously into nonobese diabetic severe combined im

194 r normal TSH, we transplanted BVE-PTC tumors subcutaneously into nude and TPO-Braf(WT) mice.

195 on adenocarcinoma cells (HT-29) were grafted subcutaneously into nude mice (n = 111).

196 iferation and immunoblot assays, or injected subcutaneously into nude mice.

197 iated fetal rat testes were xenotransplanted subcutaneously into recipient mice for 4 weeks.

198 In Ifit2(-/-) mice, VSV, injected subcutaneously into the footpad, entered the proximal ly

199 100% protection in mice challenged with WEEV subcutaneously, intranasally, or via mosquito.

200 inistered to adrenalectomized rats at 1.0 mg subcutaneously, it inhibited ACTH release for >7 d.

201 eks; all patients received evolocumab 420 mg subcutaneously monthly, or if on apheresis every 2 weeks

202 gle-dose BI 655066 intravenously (n = 18) or subcutaneously (n = 13) or placebo (n = 8).

203 bats (Rousettus aegyptiacus) were inoculated subcutaneously (n = 22) with Marburg virus (MARV).

204 presence of F573, and F573 was administered subcutaneously on days 0 to 5 posttransplant.

205 with LDAC (20 mg/m(2) per day) administered subcutaneously on days 1 to 10.

206 1-14 every 21 days), bortezomib (1.3 mg/m(2) subcutaneously on days 1, 4, 8, and 11 every 21 days), a

207 col amendment 1 then either intravenously or subcutaneously on days 1, 4, 8, and 11 for the first eig

208 nuated RVd maintenance (bortezomib 1 mg/m(2) subcutaneously on days 1, 8, and 15; lenalidomide 15 mg

209 or (300 mug/m(2) per day or 5 mug/kg per day subcutaneously on days 1-5), fludarabine (intravenous in

210 CMVPepVax was administered subcutaneously on days 28 and 56.

211 y-stimulating factor (250 mug/m(2) per dose) subcutaneously on days 6-12.

212 cted seven pregnant jills with the PR strain subcutaneously on gestational day 21, corresponding to t

213 static to lymph nodes (B16F10) was implanted subcutaneously on the dorsal hind paw of C57 mice while

214 to 3 x 10(6) reporter T cells were injected subcutaneously on the shoulder area.

215 al; 1.3 mg/m(2) intravenously or 1.6 mg/m(2) subcutaneously) on days 1 and 8 for cycles two to six.

216 venously on day 1 plus sargramostim, 250 mug subcutaneously, on days 1 to 14 of a 21-day cycle (n = 1

217 cer, were randomly assigned to EPO 40,000 IU subcutaneously once a week or best standard of care.

218 1) to inject 125 mg/mL simtuzumab or placebo subcutaneously once a week.

219 ical syringes containing placebo or anakinra subcutaneously once daily for 12 weeks.

220 ceive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle ther

221 04), adalimumab at a 40-mg dose administered subcutaneously once every 2 weeks (106), placebo with a

222 Patients received luspatercept subcutaneously once every 21 days at dose concentrations

223 kinumab 50, 150, or 300 mg or placebo, given subcutaneously once every 3 months.

224 canakinumab (50 mg, 150 mg, or 300 mg) given subcutaneously once every 3 months.

225 placebo or canakinumab (50, 150, or 300 mg) subcutaneously once every 3 months.

226 placebo or canakinumab (50, 150, or 300 mg) subcutaneously once every 3 months.

227 of pegylated interferon alfa-2a was 450 mug subcutaneously once per week, but was decreased in a ste

228 onacept monotherapy or placebo, administered subcutaneously once weekly.

229 eeks; peginterferon alfa-2a (180 ug/1.73m(2) subcutaneously) once-weekly was added at the end of week

230 analog buserelin (20 mug, 1 mg/ml) or saline subcutaneously, once daily for 5 days, followed by 3 wee

231 e lebrikizumab 37.5 mg or 125 mg, or placebo subcutaneously, once every 4 weeks.

232 multiple doses of VRC01 administered either subcutaneously or by intravenous (IV) infusion and to as

233 jected mice with prostate tumor cells either subcutaneously or intraosseously.

234 blished human HGSOC cell line growing either subcutaneously or intraperitoneally in immunocompromised

235 the survival of outbred CD1 mice challenged subcutaneously or intraperitoneally with hvKP1 was signi

236 grafts were successfully established, either subcutaneously or intraperitoneally, in nude mice.

237 lly) or placebo with bortezomib (1.3 mg/m(2) subcutaneously or intravenously and dexamethasone (20 mg

238 Delivery of Scl-Ab therapy either subcutaneously or intravenously in phase 1 and 2 human c

239 VRd group received 1.3 mg/m(2) of bortezomib subcutaneously or intravenously on days 1, 4, 8, and 11

240 days 1, 8, and 15), bortezomib (1.3 mg/m(2) subcutaneously or intravenously on days 1, 4, 8, and 11)

241 d full or a 1/3 dose of zoster vaccine given subcutaneously or one of four intradermal doses (full, 1

242 rsening asthma, whereas treatment of AR with subcutaneously or sublingual allergen immunotherapy (SLI

243 binant soluble LIGHT into naive mice, either subcutaneously or systemically, promoted collagen deposi

244 enous loading bolus, followed by 10 mg daily subcutaneously) or placebo during plasma exchange and fo

245 0.5% L-bupivacaine and 1% lidocaine injected subcutaneously) or regional (brachial plexus block [BPB]

246 066 intravenously, 0.25 or 1 mg/kg BI 655066 subcutaneously, or matched placebo.

247 o model in which TLR2 agonists were injected subcutaneously over the skull bones.

248 The subcutaneously placed device can be activated using an e

249 stration dose-dependently (0.562, 1.0 mg/kg; subcutaneously) reduced relapse-like alcohol self-admini

250 COVID-19 patients received 700mg leronlimab subcutaneously, repeated after seven days in 17/23 patie

251 Full dose zoster vaccine given subcutaneously resulted in a gpELISA geometric mean fold

252 s either intranasally, intraperitoneally, or subcutaneously resulted in over 95% survival with mean r

253 ution of monosodium glutamate (MSG) (4 mg/g) subcutaneously (s.c.) at 2nd,4th, 6th, 8th,10th postnata

254 responses with homologous protein delivered subcutaneously (s.c.), intranasally (i.n.), i.m., or tra

255 every cycle or degarelix 240 mg administered subcutaneously (SC) on day 1 of cycle 1 then 80 mg SC on

256 1a intramuscularly [IM], n = 38; IFN-beta-1a subcutaneously [SC], n = 68; IFN-beta-1b SC, n = 41; rit

257 It can be administered subcutaneously (SCIT) or sublingually (SLIT).

258 are found in the visceral cavity (vWAT) and subcutaneously (scWAT).

259 ith antibiotics administered intranasally or subcutaneously significantly reduced lung M. abscessus b

260 domly permuted blocks to receive daratumumab subcutaneously (subcutaneous group) or intravenously (in

261 lin on a sliding scale that was administered subcutaneously (target blood glucose concentration of 80

262 When administered subcutaneously, the nano-suspension formed a depot at th

263 lycine t-butyl ester; DAPT) was administered subcutaneously three times a week starting at day 28 of

264 e-cell T. vaginalis vaccine was administered subcutaneously to BALB/c mice, using a prime-boost vacci

265 lence of spores administered intranasally or subcutaneously to C57BL/6 mice but not to A/J mice, and

266 ce inoculated by 4T1 cell lines were exposed subcutaneously to plasma for 3 minutes.

267 apy, 16 mg of afamelanotide was administered subcutaneously to the combination therapy group monthly

268 When DPSC/CTL or DPSC/E106Q cells were subcutaneously transplanted into nude mice, DPSC/CTL cel

269 Six hundred syngeneic islets subcutaneously transplanted into the prevascularized gra

270 eatment, we combine microvascular meshes and subcutaneously transplanted rat islets and achieve corre

271 02 mg/kg (4% to 8% of the FDA-approved dose) subcutaneously twice daily for 6 months.

272 ody weight) or matching placebo administered subcutaneously twice daily, from 3 days before the proce

273 ly at about 12 h intervals, etanercept 50 mg subcutaneously twice weekly at about 3-4 day intervals,

274 ntiretroviral therapy received 60 mg MGN1703 subcutaneously twice weekly for 4 weeks.

275 Ang II (angiotensin II) was infused subcutaneously using osmotic mini-pumps to induce hypert

276 nously; MENSA: 75 mg intravenously or 100 mg subcutaneously) versus placebo was given at 4-week inter

277 ated that a low dose of NVP-BGJ398, injected subcutaneously, was able to penetrate into the growth pl

278 G-CSF, 10 mug/kg/day subcutaneously, was started Day 1 and maintained for 5 d

279 that indicate PIV5-RSV F may be administered subcutaneously, which is the preferred route for vaccina

280 tailored for lymphatic uptake, administered subcutaneously, will have decreased drug resistance and

281 Mice injected subcutaneously with 1,4-DPCA/hydrogel at the onset of pe

282 of (212)Pb-daratumumab, mice were engrafted subcutaneously with 5 x 10(6) RPMI8226 cells.

283 of (212)Pb-Daratumumab, mice were engrafted subcutaneously with 5.106 RPMI8226 cells.

284 nkeys (Cercopithecus aethiops) were injected subcutaneously with a dose of 10(9) KUN VLPs per animal

285 s theory, we immunized female C3H/HeOuJ mice subcutaneously with a genetically derived Hly toxoid or

286 ch diets were treated with TCDD and injected subcutaneously with AHR-competent Hepa1-GFP hepatoma cel

287 t-labile toxin (LT) from Escherichia coli or subcutaneously with aluminum hydroxide (Alum)-adsorbed r

288 Immunohistochemistry of mice treated subcutaneously with C2C showed colocalization of subunit

289 IgG levels were studied in subjects treated subcutaneously with either omalizumab or placebo.

290 Cats (n = 12) were treated subcutaneously with either saline solution or 0.3 mg/kg

291 erformed on 2 groups of SCID mice inoculated subcutaneously with increasing numbers of human NKs in t

292 10 after virus exposure, we injected animals subcutaneously with NmAbs and quantified systemic distri

293 in mouse cells and in livers of mice treated subcutaneously with PS-ASO, indicating a conserved mecha

294 pressed by > 95% and 41% in subjects treated subcutaneously with QGE031 (2 mg/kg) or omalizumab, resp

295 eptozotocin to induce diabetes and implanted subcutaneously with slow-release devices of insulin.

296 udy, a group of sheep (n = 5) was vaccinated subcutaneously with the glycoprotein-based subunit vacci

297 five to thirty-five percent of mice infected subcutaneously with Zika virus developed motor deficits

298 Three additional macaques inoculated subcutaneously with Zika virus served as saliva donors t

299 Syngeneic mouse islets were transplanted subcutaneously within Sernova Corp's Cell Pouch (CP).

300 lobulin G (IgG) antibodies when administered subcutaneously without an additional adjuvant.